2019 Archive

Research

SJELIOT clinical trial explores a new approach for recurring and unresponsive medulloblastoma tumors

Gary Bridgman

St. Jude is testing adult cancer drug prexasertib in children with recurrent or refractory medulloblastoma to inhibit checkpoint kinase chk1/2.

Investigator Insights

The 17 Samurai

Hiroto Inaba, MD, PhD

Hiroto Inaba: scientist, pediatric oncologist and "first son" of an old samurai family. His unfortunate enemy: childhood cancer.

Clinical

Patient care and clinical informatics: creating balance between technology and clinical care

Kerry Hillis Goff

A physician scientist updates the St. Jude model of research and clinical care, transforming clinical informatics.

Research

Acute lymphoblastic leukemia: collaborations in China showcase the power of global cancer care

Ching-Hon Pui, MD

An agreement between one U.S. hospital and two Chinese hospitals in 1991 has completely changed global pediatric cancer care.

Research

Optimizing leukemia treatment through pharmaceutical science

Mary Relling, PharmD

Effective leukemia treatment is one thing – making sure it’s optimized with minimal implications is another. Read research juggles both to help patients.

Research

Discovering how T cell “exhaustion” is triggered could energize cancer immunotherapy

Ben Youngblood, PhD

Read how the discovery of this gene could change immunotherapy cancer and viral infection treatments.

Clinical

‘Black hole’ of cancer journey? Transition oncology program fills the gap

Keith Crabtree, PhD

You’re just out of cancer treatment – now what? Read about the transition oncology program that helps young cancer patients get back to living.

Research

Enzymes that unlock stress granules, our cells’ biological ‘storm shelters,’ open pathway to treating muscle, brain disorders

Mondira Kundu, MD, PhD

Stress granules form from heat shock to the cell then disappear, but when treated with an inhibitor to the protein ULK, the stress granules persist event after removal of the stress.

Research

Length matters in dipeptide repeat polypeptides – and can be a way to treat ALS

Richard Kriwacki, PhD

Read how the length of these proteins may be an indicator of ALS.

Research

Exploring survivorship: The when and how of treatment strategies matter in adult survivors of childhood ALL

Mike O’Kelly

It used to be just about surviving–now, it’s about treating children with ALL to live long, healthy lives. Learn about ALL survivorship research from ASCO.